- Publikační typ
- abstrakt z konference MeSH
- Publikační typ
- abstrakt z konference MeSH
- Publikační typ
- abstrakt z konference MeSH
BACKGROUND: Epigenetic mechanisms have important roles in the tumour escape from immune responses, such as in MHC class I downregulation or altered expression of other components involved in antigen presentation. Chemotherapy with DNA methyltransferase inhibitors (DNMTi) can thus influence the tumour cell interactions with the immune system and their sensitivity to immunotherapy. METHODS: We evaluated the therapeutic effects of the DNMTi 5-azacytidine (5AC) against experimental MHC class I-deficient and -positive tumours. The 5AC therapy was combined with immunotherapy, using a murine model for HPV16-associated tumours. RESULTS: We have demonstrated 5AC additive effects against MHC class I-positive and -deficient tumours when combined with unmethylated CpG oligodeoxynucleotides or with IL-12-producing cellular vaccine. The efficacy of the combined chemoimmunotherapy against originally MHC class I-deficient tumours was partially dependent on the CD8(+)-mediated immune responses. Increased cell surface expression of MHC class I cell molecules, associated with upregulation of the antigen-presenting machinery-related genes, as well as of genes encoding selected components of the IFNγ-signalling pathway in tumours explanted from 5AC-treated animals, were observed. CONCLUSION: Our data suggest that chemotherapy of MHC class I-deficient tumours with 5AC combined with immunotherapy is an attractive setting in the treatment of MHC class I-deficient tumours.
- MeSH
- antimetabolity antitumorózní farmakologie MeSH
- azacytidin farmakologie MeSH
- DNA primery MeSH
- ELISA MeSH
- experimentální nádory farmakoterapie imunologie terapie virologie MeSH
- histokompatibilita - antigeny třídy I imunologie MeSH
- imunoterapie MeSH
- kvantitativní polymerázová řetězová reakce MeSH
- lidský papilomavirus 16 izolace a purifikace MeSH
- metylace MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- sekvence nukleotidů MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- MeSH
- finanční podpora výzkumu jako téma MeSH
- histokompatibilita - antigeny třídy I biosyntéza MeSH
- imunoterapie metody MeSH
- infekce papilomavirem imunologie MeSH
- myši MeSH
- nádory imunologie virologie MeSH
- onkogenní proteiny virové biosyntéza MeSH
- Papillomaviridae metabolismus MeSH
- regulace genové exprese u nádorů MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- MeSH
- dendritické buňky imunologie MeSH
- experimentální nádory terapie MeSH
- finanční podpora výzkumu jako téma MeSH
- infekce papilomavirem komplikace MeSH
- myši MeSH
- onkogenní proteiny virové MeSH
- Papillomaviridae imunologie MeSH
- protinádorové vakcíny MeSH
- represorové proteiny imunologie MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
